RT Journal Article
SR Electronic
T1 <em>KRAS</em> mutations impact clinical outcome in metastatic non-small cell lung cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.27.21266822
DO 10.1101/2021.11.27.21266822
A1 Eklund, Ella A.
A1 Wiel, Clotilde
A1 Fagman, Henrik
A1 Akyürek, Levent M.
A1 Raghavan, Sukanya
A1 Nyman, Jan
A1 Hallqvist, Andreas
A1 Sayin, Volkan I.
YR 2022
UL http://medrxiv.org/content/early/2022/02/14/2021.11.27.21266822.abstract
AB Purpose There is an urgent need to identify new predictive biomarkers for treatment response to both platinum doublet chemotherapy (PD) and immune checkpoint blockade (ICB) with pembrolizumab. Here we evaluated whether treatment outcome could be affected by KRAS mutational status in patients with metastatic (stage IV) non-small cell lung cancer (NSCLC).Methods All consecutive patients molecularly assessed and diagnosed between 2016-2018 with stage IV NSCLC in the region of West Sweden were included in this multi-center retrospective study. Primary study outcome was overall survival (OS).Results Out of 580 stage IV NSCLC patients, 35.5% harbored an activating mutation in the KRAS gene (KRASMUT). Compared to KRAS wild-type (KRASWT), KRASMUT was a negative factor for OS (p = 0.014). On multivariate analysis, KRASMUT persisted as a negative factor for OS (HR 1.288, 95% CI 1.091-1.521, p = 0.003). When treated with first-line platinum doublet (n = 195), KRASMUT is a negative factor for survival (p = 0.018) with median OS 9 months vs KRASWT 11 months. On multivariate analysis, KRASMUT persisted as a negative factor for OS (HR 1.564, 95%CI 1.124-2.177, p = 0.008). KRASMUT patients with high PD-L1 expression (PD-L1high) had better OS than PD-L1high KRASWT patients (p = 0.036). In response to first-line ICB, KRASMUT patients had a significant (p = 0.006) better outcome than KRASWT with a median OS 23 vs 6 months. On multivariable Cox analysis, KRASMUT status was an independent prognostic factor for better OS (HR 0.349, 95%CI 0.148-0.822, p = 0.016).Conclusions KRAS mutations is a positive predictive factor for treatment with pembrolizumab and a negative predictive factor for platinum doublet chemotherapy as well as general OS in stage IV NSCLC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swedish Society for Medical Research (2018; S18-034), the Swedish Cancer Society, the Medical Research Council (2018; 2018-02318), AG Fond (2020), the Knut and Alice Wallenberg Foundation and the Wallenberg Centre for Molecular and Translational Medicine (to V.I.S.); the Gothenburg Society of Medicine (2019; 19/889991) and Department of Oncology, Sahlgrenska University Hospital (to E.A.E.); the Swedish Cancer Society and The Healthcare Board for the Region of West Sweden (to S.R); Sahlgrenska Academy, Gothenburg University (2019; GU2019-3467) (to C.W.); the Swedish government under the LUA/ALF agreement (to H.F.); the Swedish Cancer Society (2017; 17-0171) and the Swedish government under the LUA/ALF agreement (ALFGBG-495961) (to L.M.A.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Swedish Ethical Review Authority gave approval for this work (Dnr 2019-04771)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsECOGEastern Cooperative Oncology Group;ICBImmune Checkpoint Blockade;NSCLCNon-Small Cell Lung Cancer;NGSNext Generation Sequencing;PDPlatinum Doublet;PD-1Programmed Cell Death 1;PD-L1Programmed Death Ligand 1;PSPerformance Status;OSOverall Survival;TPSTumor Proportion Score